文献速递乳腺癌支持与姑息治疗

可改变风险因素与辅助内分泌治疗早期停药的相关性:随机临床试验的事后分析

Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy: A Post Hoc Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2021-06-17

该事后分析纳入TAILORx试验中954例激素受体阳性、ERBB2阴性、腋窝淋巴结阴性的乳腺癌患者,评估辅助内分泌治疗早期停药与可改变风险因素、多重用药及合并用药类型的关联。结果显示,化疗内分泌治疗及年龄大于40岁与较低的早期停药风险相关;而抑郁史、较差的身体健康状况和较差的社会健康状况与较高的早期停药风险相关;仅基线抗抑郁药使用与早期停药相关。

要点

  • 抑郁史、较差的身体健康状况和较差的社会健康状况是早期停药的独立风险因素。
  • 化疗内分泌治疗及年龄大于40岁与较低的早期停药风险相关。
  • 基线抗抑郁药使用与早期停药相关,支持系统筛查患者报告结局和抑郁症状。

核心结论

  • 基线患者报告的健康相关生活质量成分(如较差的社会健康状况、较差的身体健康状况)和合并抑郁是内分泌治疗早期停药的显著风险因素。
  • 这些结果支持系统筛查患者报告结局和抑郁症状,以识别有停药风险的女性。

研究设计与样本

  • TAILORx随机临床试验的事后分析,纳入954例激素受体阳性、ERBB2阴性、腋窝淋巴结阴性的乳腺癌患者,所有参与者均在研究入组一年内开始内分泌治疗。
  • 分析在意向治疗人群中进行,采用Kaplan-Meier估计计算停药率,Cox比例风险回归联合预测模型分析依从性与患者因素关联。

关键数值与推荐

  • 早期停药定义为开始内分泌治疗后不足4年因非死亡或复发原因停药。

临床怎么用

  • 建议系统筛查患者报告结局和抑郁症状,以识别有内分泌治疗停药风险的女性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Early discontinuation of adjuvant endocrine therapy (ET) is problematic among breast cancer survivors, with previous studies suggesting that up to 50% of women do not adhere to the recommended full 5 years of ET treatment. OBJECTIVE: To identify the association between early discontinuation of ET in the Trial Assigning Individualized Options for Treatment (TAILORx) and modifiable risk factors, polypharmacy, and types of additional medications such as antidepressants and opioids. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis includes a subgroup of 954 patients with breast cancer in TAILORx, a randomized clinical trial conducted from April 7, 2006, to October 6, 2010. All participants received a diagnosis of hormone receptor-positive, ERBB2-negative, axillary node-negative breast cancer and started ET within a year of study entry. Analyses were conducted in the intent-to-treat population. Statistical analysis took place from January 15, 2020, to April 6, 2021. MAIN OUTCOMES AND MEASURES: Participants completed measures on cancer-related health-related quality of life including physical well-being and social well-being prior to initiating ET. Early discontinuation of ET was defined as discontinuation less than 4 years from initiation for reasons other than death or recurrence. Kaplan-Meier estimates were used to calculate discontinuation, and Cox proportional hazards regression joint prediction models were used to analyze the association between rates of adherence to ET with patient-level factors. RESULTS: A total of 954 women (mean [SD] age, 56.6 [8.9] years) were included in this analysis. In a joint model, receipt of chemoendocrine therapy (vs receipt of ET only; hazard ratio [HR], 0.57; 95% CI, 0.35-0.92; P = .02) and age older than 40 years (vs ≤40 years; HR for 41-50 years, 0.39; 95% CI, 0.18-0.85; P = .02; HR for 51-60 years, 0.28; 95% CI, 0.13-0.60; P = .001; HR for 61-70 years, 0.40; 95% CI, 0.18-0.86; P = .02; and HR for >70 years, 0.23; 95% CI, 0.07-0.77; P = .02) were associated with a lower probability of early discontinuation of ET. Adjusted for these factors, a history of depression compared with no history of depression (HR, 1.82; 95% CI, 1.19-2.77; P = .005), worse physical well-being compared with better physical well-being (HR, 2.12; 95% CI, 1.30-3.45; P = .002), and worse social well-being compared with better social well-being (HR, 1.94; 95% CI, 1.20-3.13; P = .006) were individually and significantly associated with a higher probability of early discontinuation of ET. Only antidepressant use at study baseline was associated with early discontinuation (HR, 1.87; 95% CI, 1.23-2.84; P = .003). CONCLUSIONS AND RELEVANCE: In this post hoc analysis of a randomized clinical trial, baseline patient-reported health-related quality of life components, such as poor social well-being, poor physical well-being, and comorbid depression, were significant risk factors for early discontinuation of endocrine therapies. These results support systematic screening for patient-reported outcomes and depressive symptoms to identify women at risk for discontinuation of ET. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00310180.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Yanez B, Gray RJ, Sparano JA, et al. Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 34137783. doi:10.1001/jamaoncol.2021.1693

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。